These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 220051)

  • 41. IgA antibodies to Epstein-Barr viral capsid antigens in saliva of nasopharyngeal carcinoma patients.
    Ho HC; Ng MH; Kwan HC
    Br J Cancer; 1977 Jun; 35(6):888-90. PubMed ID: 194619
    [No Abstract]   [Full Text] [Related]  

  • 42. Enzyme-linked immunosorbent assay (ELISA) for IgA and IgG antibodies to Epstein-Barr-virus ribonucleotide reductase in patients with nasopharyngeal carcinoma.
    Fones-Tan A; Chan SH; Tsao SY; Gan LH; Tan WH; Li B; Khong PW; Gan YY
    Int J Cancer; 1994 Dec; 59(6):739-42. PubMed ID: 7989110
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epstein-Barr virus specific IgA serum antibodies in nasopharyngeal and other respiratory carcinomas.
    Desgranges C; de-Thé G
    Int J Cancer; 1979 Nov; 24(5):555-9. PubMed ID: 231014
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differences in EBV antibody titres of patients with nasopharyngeal carcinoma originating from high, intermediate and low incidence areas.
    de-The G; Lavoue MF; Muenz L
    IARC Sci Publ (1971); 1978; (20):471-81. PubMed ID: 215529
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Rhinopharyngeal carcinoma and Epstein-Barr virus: study of a sample of Italian patients].
    Caliceti U; Cevenini R; Donati M
    Acta Otorhinolaryngol Ital; 1985; 5(1):83-90. PubMed ID: 2994355
    [No Abstract]   [Full Text] [Related]  

  • 46. Serum anti-EBV IgA is inversely related to tumor infiltration by surface IgA positive lymphocytes in nasopharyngeal carcinoma.
    Gunvén P; Klein G; Henle W; Henle G; Forsby N
    Biomed Pharmacother; 1983; 37(1):41-4. PubMed ID: 6311307
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibodies to Epstein-Barr virus capsid antigen and early antigen in nasopharyngeal carcinoma and comparison groups.
    Lin TM; Yang CS; Chiou JF; Tu SM; Chen TY; Tu YC; Lin PJ; Kawamura A; Hirayama T
    Am J Epidemiol; 1977 Oct; 106(4):336-9. PubMed ID: 199059
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An immunoperoxidase assay for the detection of specific IgA antibody in Epstein-Barr virus infections.
    Cevenini R; Donati M; Rumpianesi F; Moroni A; Paolucci P
    J Clin Pathol; 1984 Apr; 37(4):440-3. PubMed ID: 6323549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epstein-Barr virus serology in nasopharyngeal carcinomas and other head and neck neoplasms in Italy.
    Faggioni A; Corradini C; Barile G; Cardi G; Ciarniello V; Venenzoni M; Zompetta C; Maurizi M; Paludetti G; Manzari V
    J Cancer Res Clin Oncol; 1985; 110(2):157-60. PubMed ID: 2995399
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epstein-Barr virus antibodies in Sudanese patients with nasopharyngeal carcinoma: a preliminary report.
    Malik MO; Banatvala J; Hutt MS; Abu-Sin AY; Hidaytallah A; El-Hadi AE
    J Natl Cancer Inst; 1979 Feb; 62(2):221-4. PubMed ID: 216831
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-EBV serologic tests for nasopharyngeal carcinoma.
    Neel HB; Pearson GR; Weiland LH; Taylor WF; Goepfert HH; Pilch BZ; Lanier AP; Huang AT; Hyams VJ; Levine PH; Henle G; Henle W
    Laryngoscope; 1980 Dec; 90(12):1981-90. PubMed ID: 6256597
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins.
    Littler E; Baylis SA; Zeng Y; Conway MJ; Mackett M; Arrand JR
    Lancet; 1991 Mar; 337(8743):685-9. PubMed ID: 1672175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infections.
    Linde A; Andersson J; Lundgren G; Wahren B
    J Med Virol; 1987 Feb; 21(2):109-21. PubMed ID: 3029317
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nasopharyngeal carcinoma and Epstein-Barr virus. I. Factors related to the anti-VCA antibody.
    Lynn T; Tu S; Hirayama T; Kawamura A
    Jpn J Exp Med; 1973 Apr; 43(2):121-33. PubMed ID: 4352111
    [No Abstract]   [Full Text] [Related]  

  • 55. Antibodies to Epstein-Barr virus in patients with nasopharyngeal carcinoma in Northern Ireland.
    Coyle PV; Wyatt D; Connolly JH; Lynch GA
    Ir J Med Sci; 1987 Jun; 156(6):182-4. PubMed ID: 3040619
    [No Abstract]   [Full Text] [Related]  

  • 56. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma and other neoplastic conditions.
    Kottaridis SD; Dafnou M; Besbeas S; Garas J
    J Natl Cancer Inst; 1977 Jul; 59(1):89-91. PubMed ID: 195074
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of IgA antibody to EBV membrane antigen using Staphylococcus aureus preabsorbed sera is closely associated with nasopharyngeal carcinoma.
    Pi GH; Zeng Y; Wolf H
    J Virol Methods; 1987 Jan; 15(1):33-9. PubMed ID: 3027115
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
    Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
    Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epstein-Barr virus-specific serodiagnostic tests in carcinomas of the head and neck.
    Ringborg U; Henle W; Henle G; Ingimarsson S; Klein G; Silfversward C; Strander H
    Cancer; 1983 Oct; 52(7):1237-43. PubMed ID: 6309355
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nasopharyngeal carcinoma in American Children: Epstein-Barr virus-specific antibody titers and prognosis.
    Naegele RF; Champion J; Murphy S; Henle G; Henle W
    Int J Cancer; 1982 Feb; 29(2):209-12. PubMed ID: 6174465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.